Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Next Previous
X
Search
Trial Profile

This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Step by Step
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 09 Nov 2022 Results assessing the short-term cost-effectiveness of insulin degludec/insulin aspart versus basal plus bolus insulin in Indian setting from Step-by-step clinical trial, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 18 May 2022 Results of a cost-effectiveness analysis of insulin degludec or insulin aspart versus insulin glargine + insulin aspart for treatment of patients with type2diabetes using data from this clinical study presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 01 Jan 2019 Primary endpoint (Change from baseline in glycosylated haemoglobin (HbA1c)) has been met, according to the published in the Diabetes Research and Clinical Practice

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top